← All trials
NCT06685809
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 9, 2024
- Primary completion
- Jul 31, 2025
- Completion date
- Aug 15, 2025
- First posted
- Nov 13, 2024
- Last posted
- Nov 21, 2024
- Enrollment
- 84
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Fermion Technology Co., LTDLead sponsor
- Guangzhou Fermion Technology Co., LTDOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.